DV
Dividend Vision

NWBO — Northwest Biotherapeutics Inc

Northwest Biotherapeutics Inc (NWBO)

Total return is -100.0% over the past 24.7 years, 1073.8 points behind SPY at 973.8%. Its deepest 1-year drawdown was 52.1%.

NWBO is a single-stock equity holding in Northwest Biotherapeutics, a biotech company focused on cancer immunotherapy treatments. The holding does not currently pay distributions and carries no dividend yield, making it unsuitable for income-focused strategies. This is a growth-oriented equity position that appeals to investors seeking exposure to biotechnology innovation rather than dividend income.

NWBO key facts

Asset type
Stock
Asset class
Equity
Distribution frequency
None
Last close
$0.19
Market cap
$312,235,296
Average volume
1431500.0
Beta
-0.62
Payout ratio
0.0
Forward P/E
12.4533
EPS
$-0.03